Dupilumab

(Dupixent®)

Dupixent®

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormPre-Filled Syringe Injection (subcutaneous; 100 mg/ 0.67 mL, 200 mg/1.14 mL, 300 mg/2 mL); Pre-Filled Pen Injection (subcutaneous; 200 mg/ 1.14 mL, 300 mg/ 2 mL)
Drug ClassInterleukin-4 receptor alpha antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
  • Indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
  • Indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
  • Indicated for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE).
  • Indicated for the treatment of adult patients with prurigo nodularis (PN).

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Dupilumab (Dupixent) is used for a variety of indications including moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.
  • A review of 31 systematic reviews/meta-analyses reveals that Dupilumab shows higher efficacy in reducing symptoms and improving the quality of life compared to placebo across various conditions.
  • In the treatment of Atopic Dermatitis (AD), it has been found beneficial, especially among pediatric populations. However, direct comparisons suggest upadacitinib and abrocitinib might offer superior short-term efficacy but often come with a higher risk of adverse events.
  • For patients suffering from asthma characterized by an eosinophilic phenotype or dependence on oral corticosteroids, Dupilumab improves lung function while reducing exacerbations; however, newer pharmaceuticals like Umeclidinium/Vilanterol may show better improvements in FEV1 measurements.
  • When treating Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP), this drug significantly improves quality-of-life measures and reduces polyp surgery risk making it one the most beneficial biologics for CRSwNP when compared to others such as omalizumab and mepolizumab.
  • Considering all indications together, high-dose upadacitinib was found to be more effective but also more harmful than Dupilumab, which offered intermediate effectiveness along with a significantly better safety profile marked by less increase in conjunctivitis compared to other drugs like lebrikizumab and tralokinumab.
  • The benefits are particularly significant among pediatric populations where studies consistently indicate symptom relief along with notable improvements in disease-specific quality-of-life measurements using Dupilumab.
  • Dupilumab's safety profile has been favorable across studies, showing lower incidence rates of serious adverse events compared to several other biologics and systemic treatments.

Product Monograph / Prescribing Information

Document TitleYearSource
Dupixent (Dupilumab) Prescribing Information.2022Regeneron Pharmaceuticals., Tarrytown, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy of dupilumab plus topical corticosteroids in children with atopic dermatitis: a meta-analysis of randomized controlled trials.2024Immunity, Inflammation and Disease
Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.2024British Journal of Dermatology
Effectiveness of systemic treatments on pruritus associated with atopic dermatitis: a systematic review in pediatric patients.2024Pediatric Dermatology
Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease.2024Frontiers in Medicine
Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.2023Heliyon
Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials.2023Journal of Allergy and Clinical Immunology
A comparison of the effectiveness of biologic therapies for asthma: a systematic review and network meta-analysis.2023Annals of Allergy, Asthma, and Immunology
The effect of biologics in lung function and quality of life of patients with united airways disease: a systematic review.2023Journal of Allergy and Clinical Immunology
Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: a systematic review and meta-analysis.2023Heliyon
Dupilumab in inflammatory skin diseases: a systematic review.2023Biomolecules
Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis.2022JAMA Dermatology
Dupilumab efficacy and safety in patients with moderate to severe asthma: a systematic review and meta-analysis.2022Frontiers in Pharmacology
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis.2022Journal of Allergy and Clinical Immunology
Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: a systematic literature review and meta-analysis.2022Frontiers in Medicine
Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers: a systematic review and network meta-analysis.2022Cells
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. 2022Journal of Medical Economics
Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis.2021Expert Review of Clinical Pharmacology
Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis.2021Journal of the European Academy of Dermatology and Venereology
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. 2021Rhinitis, Sinusitis, and Ocular Allergy
Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for people with asthma.2021Cochrane Database of Systematic Review
Biological therapies for atopic dermatitis: a systematic review.2021Dermatology
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.2021Journal of the European Academy of Dermatology and Venereology
Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. 2021Allergy
Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. 2020JAMA Dermatology
Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis.2020Current Medical Research and Opinion
Comparative efficacy and safety of dupilumab and benralizumab in patients with inadequately controlled asthma: a systematic review.2020International Journal of Molecular Sciences
Biologics for chronic rhinosinusitis. 2020Cochrane Database of Systematic Reviews
Systemic treatments for eczema: a network meta‐analysis.2020The Cochrane Database of Systematic Reviews
Use of dupilumab on the treatment of moderate-to-severe asthma: a systematic review.2019Revista da Associação Médica Brasileira
Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.2019Respiratory Research
Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials.2019Respiratory Research

Clinical Practice Guidelines